Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer(,,)

OBJECTIVE: Farletuzumab is a humanized monoclonal antibody that binds to folate receptor alpha, over-expressed in epithelial ovarian cancer (EOC) but largely absent in normal tissue. Previously, carboplatin plus pegylated liposomal doxorubicin showed superior progression-free survival and an improve...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Gynecol Oncol
Prif Awduron: Kim, Kenneth H., Jelovac, Danijela, Armstrong, Deborah K., Schwartz, Benjamin, Weil, Susan C., Schweizer, Charles, Alvarez, Ronald D.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4729193/
https://ncbi.nlm.nih.gov/pubmed/26644263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.11.031
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg